MRKR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Marker Therapeutics Inc (MRKR) is not a strong buy at the moment for a beginner investor with a long-term strategy. The company's financial performance is weak, with declining revenue, net income, and EPS. While the technical indicators are neutral and there are no strong trading signals, the analyst rating is positive with a high price target, suggesting potential long-term growth. However, without significant positive catalysts or strong financial performance, it is better to hold off on investing right now.
The MACD histogram is positive and expanding, indicating a potential bullish trend. RSI is neutral at 55.844, and moving averages are converging, suggesting no clear trend. Key support and resistance levels are pivot: 1.525, R1: 1.642, S1: 1.408, R2: 1.713, S2: 1.337. The pre-market price is below the pivot, indicating potential weakness in the short term.
The analyst rating from H.C. Wainwright is positive, with a Buy rating and a $10 price target. The company's pipeline of MAR-T cell therapies positions it as a potential leader in cancer immunotherapy.
There are no significant trading trends from hedge funds or insiders, and no recent news or congress trading data to act as catalysts.
In Q3 2025, revenue dropped by -35.99% YoY to $1,232,938. Net income decreased by -13.41% YoY to -$1,998,662. EPS fell by -53.85% YoY to -0.12. Gross margin remained steady at 100%. Overall, the financial performance shows significant weakness.
H.C. Wainwright initiated coverage with a Buy rating and a $10 price target, citing the potential of the company's MAR-T cell therapies to overcome limitations in cancer immunotherapy.
